Exelixis Inc. (EXEL)

16.92
NASDAQ : Health Technology
Prev Close 16.92
Day Low/High 0.00 / 0.00
52 Wk Low/High 15.49 / 32.20
Avg Volume 3.32M
Exchange NASDAQ
Shares Outstanding 298.04M
Market Cap 4.74B
EPS 0.50
P/E Ratio 15.44
Div & Yield N.A. (N.A)

Latest News

3 Small Biotech Stocks to Watch in the Fourth Quarter

3 Small Biotech Stocks to Watch in the Fourth Quarter

These are just a few of the names I expect to do well to close out 2018.

3 Small Biotechs on My Q4 Watch List

3 Small Biotechs on My Q4 Watch List

These are a few of the names I expect to do well to close out 2018.

Exelixis Larger Than S&P 500 Component Stericycle

Exelixis Larger Than S&P 500 Component Stericycle

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Exelixis Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Stericycle Inc. , according to The Online Investor.

Exelixis To Present At The Cantor Fitzgerald Global Healthcare Conference On October 2, 2018

Exelixis To Present At The Cantor Fitzgerald Global Healthcare Conference On October 2, 2018

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis' Partner Ipsen Announces Positive CHMP Opinion For CABOMETYX® (cabozantinib) Tablets For Previously Treated Hepatocellular Carcinoma

Exelixis' Partner Ipsen Announces Positive CHMP Opinion For CABOMETYX® (cabozantinib) Tablets For Previously Treated Hepatocellular Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX ® (cabozantinib)...

Synchrony, Exelixis Look Like Good Values

Synchrony, Exelixis Look Like Good Values

The credit card provider and the biotech concern appear cheap relative to their potential.

Exelixis' Partner Ipsen Announces Health Canada's Approval Of CABOMETYX® (cabozantinib) Tablets For The Treatment Of Adults With Previously Treated Advanced Renal Cell Carcinoma

Exelixis' Partner Ipsen Announces Health Canada's Approval Of CABOMETYX® (cabozantinib) Tablets For The Treatment Of Adults With Previously Treated Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada Inc.

Exelixis Announces New Recommendations For CABOMETYX® (Cabozantinib) Tablets In Updated National Comprehensive Cancer Network Clinical Practice Guidelines

Exelixis Announces New Recommendations For CABOMETYX® (Cabozantinib) Tablets In Updated National Comprehensive Cancer Network Clinical Practice Guidelines

Exelixis, Inc. (NASDAQ:EXEL) today announced that the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX ® (cabozantinib) tablets.

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Jim Cramer, celebrating the opening of the NFL season, says this is just another day of total tech mayhem.

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

Jim Cramer takes a look at United Parcel Service, TJX Companies, Anheuser-Busch InBev, Fiat Chrysler, AbbVie, Nvidia, Excelixis, Bank of America, Endo Pharmaceutical and more.

Exelixis To Present At The Morgan Stanley Global Health Care Conference On September 12, 2018

Exelixis To Present At The Morgan Stanley Global Health Care Conference On September 12, 2018

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Announces Second Quarter 2018 Financial Results And Provides Corporate Update

Exelixis Announces Second Quarter 2018 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2018 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

Exelixis To Release Second Quarter 2018 Financial Results On Wednesday, August 1, 2018

Exelixis To Release Second Quarter 2018 Financial Results On Wednesday, August 1, 2018

Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2018 financial results will be released on Wednesday, August 1, 2018 after the markets close.

Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published In The New England Journal Of Medicine

Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published In The New England Journal Of Medicine

Exelixis, Inc. (Nasdaq: EXEL) today announced that The New England Journal of Medicine ( NEJM) published results from the CELESTIAL phase 3 pivotal trial of cabozantinib in patients with previously treated advanced hepatocellular carcinoma (HCC).

Exelixis To Be Added To The S&P MidCap 400 Index

Exelixis To Be Added To The S&P MidCap 400 Index

Exelixis, Inc. (Nasdaq: EXEL) today announced that it will be added to Standard & Poor's (S&P) MidCap 400 index, effective prior to the open of trading on Monday, July 2.

Copart Set To Join S&P 500; Exelixis To Join S&P MidCap 400; Clarifications To S&P U.S. Indices Methodology

Copart Set To Join S&P 500; Exelixis To Join S&P MidCap 400; Clarifications To S&P U.S. Indices Methodology

NEW YORK, June 25, 2018 /PRNewswire/ -- S&P MidCap 400 constituent Copart Inc. (NASD:CPRT) will replace Dr Pepper Snapple Group Inc.

First Week Of EXEL February 2019 Options Trading

First Week Of EXEL February 2019 Options Trading

Investors in Exelixis Inc saw new options begin trading this week, for the February 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Sirius XM Radio, Molson Coors, MSCI: 'Mad Money' Lightning Round

Sirius XM Radio, Molson Coors, MSCI: 'Mad Money' Lightning Round

Jim Cramer takes a look at Sirius XM Radio, Molson Coors, MSCI, Exelixis, SemGroup, Flagstar Bancorp, PPL Corp., Kratos Defense & Security.

Who Are the Trade War Victims?: Cramer's 'Mad Money' Recap (Tues. 6/19/18)

Who Are the Trade War Victims?: Cramer's 'Mad Money' Recap (Tues. 6/19/18)

Jim Cramer says the U.S. has the upper hand when it comes to the tariffs because we import far more from China than they import from us.

Exelixis To Present At The William Blair & Co. 38th Annual Growth Stock Conference On June 12, 2018

Exelixis To Present At The William Blair & Co. 38th Annual Growth Stock Conference On June 12, 2018

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Announces Results From Sub-Group Analyses Of The Phase 3 Pivotal CELESTIAL Trial Of Cabozantinib For Advanced Hepatocellular Carcinoma Presented At ASCO 2018

Exelixis Announces Results From Sub-Group Analyses Of The Phase 3 Pivotal CELESTIAL Trial Of Cabozantinib For Advanced Hepatocellular Carcinoma Presented At ASCO 2018

Exelixis, Inc. (Nasdaq: EXEL) today announced results from sub-group analyses of the CELESTIAL phase 3 pivotal trial of cabozantinib in advanced hepatocellular carcinoma (HCC) comparing outcomes by duration of sorafenib treatment in patients whose only...

Exelixis Announces Further Expansion To Clinical Research Protocol For Phase 1b COSMIC-021 Trial Of Cabozantinib In Combination With Anti-PD-L1 Immunotherapy In Patients With Locally Advanced Or Metastatic Solid Tumors

Exelixis Announces Further Expansion To Clinical Research Protocol For Phase 1b COSMIC-021 Trial Of Cabozantinib In Combination With Anti-PD-L1 Immunotherapy In Patients With Locally Advanced Or Metastatic Solid Tumors

Exelixis, Inc. (Nasdaq:EXEL) today announced an amendment to the protocol for COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX ®) in combination with atezolizumab (TECENTRIQ ®) in patients with locally advanced or metastatic solid tumors to add...

Exelixis Appoints Andrew R. Peters To Newly Created Position Of Vice President, Strategy

Exelixis Appoints Andrew R. Peters To Newly Created Position Of Vice President, Strategy

Exelixis, Inc. (NASDAQ: EXEL) today announced the appointment of Andrew R.

Exelixis' Partner Ipsen Announces European Commission Approval Of CABOMETYX® (Cabozantinib) For Previously Untreated Intermediate- Or Poor-Risk Advanced Renal Cell Carcinoma

Exelixis' Partner Ipsen Announces European Commission Approval Of CABOMETYX® (Cabozantinib) For Previously Untreated Intermediate- Or Poor-Risk Advanced Renal Cell Carcinoma

Exelixis, Inc. (Nasdaq:EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX ® (cabozantinib) 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced...

Exelixis Provides Update On IMblaze370 Phase 3 Pivotal Trial Of Atezolizumab And Cobimetinib In Patients With Heavily Pretreated Locally Advanced Or Metastatic Colorectal Cancer

Exelixis Provides Update On IMblaze370 Phase 3 Pivotal Trial Of Atezolizumab And Cobimetinib In Patients With Heavily Pretreated Locally Advanced Or Metastatic Colorectal Cancer

Exelixis, Inc. (Nasdaq:EXEL) today announced that IMblaze370, the phase 3 pivotal trial of atezolizumab (TECENTRIQ ®), an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group, and cobimetinib (COTELLIC ®), an...

Exelixis To Present At The Bank Of America Merrill Lynch Health Care Conference On May 15, 2018

Exelixis To Present At The Bank Of America Merrill Lynch Health Care Conference On May 15, 2018

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Two Oncology Stocks I Like Now

Two Oncology Stocks I Like Now

M&A activity should pick up in the biotech space.

TheStreet Quant Rating: C+ (Hold)